Skip to main content
. 2015 Jun 3;350:h2388. doi: 10.1136/bmj.h2388

Table 1.

Descriptive data for varenicline cohort and non-treated cohort in Sweden, 2006-09. Values are numbers (percentages)

Varenicline cohort (n=69 757) Non-treated cohort* (n=7 847 679)
Characteristics at baseline 2006
Women 43 861 (62.9) 3 964 263 (50.5)
Men 25 896 (37.1) 3 883 417 (49.5)
Age distribution:
<20 408 (0.6) 982 116 (12.5)
20-29 3744 (5.4) 1 084 733 (13.8)
30-39 9226 (13.2) 1 222 610 (15.6)
40-49 17 375 (24.9) 1 221 021 (15.6)
50-59 21 480 (30.8) 1 170 086 (14.9)
60-69 14 447 (20.7) 1 022 055 (13.0)
≥70 3077 (4.4) 1 143 656 (14.6)
Psychiatric diagnoses:
Pre-existing psychiatric diagnosis† 9391 (13.5) 484 536 (6.2)
Lifetime alcohol misuse diagnosis‡ 5562 (8.0) 197 988 (2.5)
Lifetime drug misuse diagnosis‡ 2633 (3.8) 80 535 (1.0)
Lifetime nicotine dependence diagnosis‡ 2379 (3.4) 19 392 (0.3)
Characteristics during follow-up (22 November 2006 to 31 December 2009)
Inpatient or outpatient care:
New psychiatric conditions 3213 (4.6) 168 869 (2.2)
Anxiety conditions 1816 (2.6) 88 905 (1.1)
Mood conditions 1717 (2.5) 84 931 (1.1)
Psychoses 320 (0.5) 24 384 (0.3)
Suicidal behaviour 657 (0.9) 26 093 (0.3)
Crimes:
Convicted of any crime 2256 (3.2) 204 508 (2.6)
Suspected of any crime 3782 (5.4) 311 914 (4.0)
Transport accidents and traffic offences:
Transport accident 989 (1.4) 108 612 (1.4)
Convicted of traffic offence 328 (0.5) 36 271 (0.5)
Suspected of traffic offence 440 (0.6) 46 572 (0.6)

*All people in cohort who were not treated with varenicline during follow-up.

†Diagnosed before 1 November 2006.

‡Diagnosed between 1 January 1987 and 31 December 2009.